Robin Heffernan is a serial entrepreneur, experienced executive, and former Venture Capitalist focused on healthcare and technology. Dr. Heffernan is passionate about shifting the healthcare cost curve, improving access and achieving measurable value for patients and healthcare companies.
Most recently, Dr. Heffernan was CEO of Epidemico a population health company spun out from Boston Children’s Hospital (BCH) and Harvard Medical School. Heffernan was responsible for licensing core technology out of BCH, rapidly scaling the business over the next two years and driving a successful acquisition and integration of the company with Booz Allen Hamilton.
Prior experience includes starting two other companies, Predilytics (recently acquired by Welltok) and Sample6 (still privately held), working as a Venture Capitalist at Flybridge Capital Partners and a strategy consultant at BCG focused on the healthcare industry.
Heffernan is a Chemical Engineering by training, completing her PhD and B.A. at Harvard University.